Evidence map›Paper›PMID 38400178›Full record

ArticleVaccines2024

Measuring Zero-Dose Children: Reflections on Age Cohort Flexibilities for Targeted Immunization Surveys at the Local Level.

Gustavo C Corrêa, Md Jasim Uddin, Tasnuva Wahed, Elizabeth Oliveras, Christopher Morgan, Moses R Kamya, Patience Kabatangare, Faith Namugaya, Dorothy Leab, Didier Adjakidje and 5 more

Abstract read
In one paragraph

Article in Vaccines, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Gustavo C CorrêaGavi, The Vaccine Alliance, Chemin du Pommier 40, Le Grand Saconnex, 1218 Geneva, Switzerland.ORCID 0000-0003-2125-9364
Md Jasim UddinInternational Centre for Diarrhoeal Disease Research, Bangladesh, 68 Shaheed Tajuddin Ahmed Sarani, Mohakhali, Dhaka 1212, Bangladesh.
Tasnuva WahedInternational Centre for Diarrhoeal Disease Research, Bangladesh, 68 Shaheed Tajuddin Ahmed Sarani, Mohakhali, Dhaka 1212, Bangladesh.ORCID 0000-0002-6819-8370
Elizabeth OliverasJhpiego, The Johns Hopkins University Affiliate, 1615 Thames Street, Baltimore, MD 21231, USA.
Christopher MorganJhpiego, The Johns Hopkins University Affiliate, 1615 Thames Street, Baltimore, MD 21231, USA.ORCID 0000-0003-0931-5474
Moses R KamyaInfectious Diseases Research Collaboration (IDRC), Kampala P.O. Box 7475, Uganda.ORCID 0000-0001-9106-4234
Patience KabatangareInfectious Diseases Research Collaboration (IDRC), Kampala P.O. Box 7475, Uganda.
Faith NamugayaInfectious Diseases Research Collaboration (IDRC), Kampala P.O. Box 7475, Uganda.
Dorothy LeabGaneshAID, 143 Doc Ngu, Lieu Giai, Ba Dinh, Hanoi 152960, Vietnam.
Didier AdjakidjeGaneshAID, 143 Doc Ngu, Lieu Giai, Ba Dinh, Hanoi 152960, Vietnam.
Patrick NgukuAfrican Field Epidemiology Network (AFENET), 50 Haile Selassie St, Asokoro, Abuja 900103, Nigeria.
Adam AttahiruAfrican Field Epidemiology Network (AFENET), 50 Haile Selassie St, Asokoro, Abuja 900103, Nigeria.
Jenny SequeiraThe Geneva Learning Foundation (TGLF), Av. Louis-Casaï 18, 1209 Geneva, Switzerland.
Nancy VollmerJSI Research & Training Institute, Inc. (JSI), 2733 Crystal Dr 4th Floor, Arlington, VA 22202, USA.ORCID 0000-0002-0259-0011
Heidi W ReynoldsGavi, The Vaccine Alliance, Chemin du Pommier 40, Le Grand Saconnex, 1218 Geneva, Switzerland.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Zero-dose (ZD) children is a critical objective in global health, and it is at the heart of the Immunization Agenda 2030 (IA2030) strategy. Coverage for the first dose of diphtheria-tetanus-pertussis (DTP1)-containing vaccine is the global operational indicator used to estimate ZD children. When surveys are used, DTP1 coverage estimates usually rely on information reported from caregivers of children aged 12-23 months. It is important to have a global definition of ZD children, but learning and operational needs at a country level may require different ZD measurement approaches. This article summarizes a recent workshop discussion on ZD measurement for targeted surveys at local levels related to flexibilities in age cohorts of inclusion from the ZD learning Hub (ZDLH) initiative-a learning initiative involving 5 consortia of 14 different organizations across 4 countries-Bangladesh, Mali, Nigeria, and Uganda-and a global learning partner. Those considerations may include the need to generate insights on immunization timeliness and on catch-up activities, made particularly relevant in the post-pandemic context; the need to compare results across different age cohort years to better identify systematically missed communities and validate programmatic priorities, and also generate insights on changes under dynamic contexts such as the introduction of a new ZD intervention or for recovering from the impact of health system shocks. Some practical considerations such as the potential need for a larger sample size when including comparisons across multiple cohort years but a potential reduction in the need for household visits to find eligible children, an increase in recall bias when older age groups are included and a reduction in recall bias for the first year of life, and a potential reduction in sample size needs and time needed to detect impact when the first year of life is included. Finally, the inclusion of the first year of life cohort in the survey may be particularly relevant and improve the utility of evidence for decision-making and enable its use in rapid learning cycles, as insights will be generated for the population being currently targeted by the program. For some of those reasons, the ZDLH initiative decided to align on a recommendation to include the age cohort from 18 weeks to 23 months, with enough power to enable disaggregation of key results across the two different cohort years. We argue that flexibilities with the age cohort for inclusion in targeted surveys at the local level may be an important principle to be considered. More research is needed to better understand in which contexts improvements in timeliness of DTP1 in the first year of life will translate to improvements in ZD results in the age cohort of 12-23 months as defined by the global DTP1 indicator.

Indexed as

equityimmunizationmeasurementtargeted surveyszero-dose

Identifiers

PMID38400178
PMCPMC10892624

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.